Literature DB >> 19712668

DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP.

Renata Matuo1, Fabrício Garmus Sousa, Alexandre E Escargueil, Daniele G Soares, Ivana Grivicich, Jenifer Saffi, Annette K Larsen, João Antonio Pêgas Henriques.   

Abstract

5-Fluorouracil (5-FU) is an antitumor antimetabolite that can be converted into fluoronucleotides and FdUMP. Fluoronucleotides are incorporated into DNA and RNA, while FdUMP results in nucleotide pool imbalance. Saccharomyces cerevisiae is unable to convert 5-FU into FdUMP, making yeast a unique model system to study the cellular effects of 5-FU and FdUMP independently. A panel of repair-deficient yeast strains was used to identify the DNA repair pathways needed for repair of lesions generated by 5-FU or FdUMP. This included yeast deficient in base excision repair (BER), nucleotide excision repair (NER), translesion synthesis (TLS), mismatch repair (MMR), post-replication repair (PRR), homologous recombination (HR) and non-homologous end-joining (NHEJ). The results revealed an important role of BER, since BER-mutants (ntg1, ntg2, apn1, apn2) showed pronounced sensitivity to both 5-FU and FdUMP. MMR mutants also showed high sensitivity to both compounds. In contrast, deficiencies in NER, NHEJ and TLS repair had only minor influence on the sensitivity to FU and FdUMP. Interestingly, deficiencies in HR (rad52) and PPR (rad6, rad18) were associated with increased sensitivity to 5-FU, but not to FdUMP. Taken together, our study reveals an important contribution of DNA repair pathways on the sensitivity to 5-FU and its active metabolite FdUMP. Importantly, the repair mechanisms differed for the 2 antimetabolites since lesions induced by 5-FU were repaired by BER, MMR, HR and PRR, while only BER and MMR were required for repair of FdUMP-induced lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712668     DOI: 10.1016/j.bcp.2009.08.016

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Dynamics of uracil and 5-fluorouracil in DNA.

Authors:  Jared B Parker; James T Stivers
Journal:  Biochemistry       Date:  2011-01-13       Impact factor: 3.162

2.  Apurinic/apyrimidinic endonuclease 2 is necessary for normal B cell development and recovery of lymphoid progenitors after chemotherapeutic challenge.

Authors:  Jeroen E J Guikema; Rachel M Gerstein; Erin K Linehan; Erin K Cloherty; Eric Evan-Browning; Daisuke Tsuchimoto; Yusaku Nakabeppu; Carol E Schrader
Journal:  J Immunol       Date:  2011-01-12       Impact factor: 5.422

3.  The anti-cancer drug 5-fluorouracil affects cell cycle regulators and potential regulatory long non-coding RNAs in yeast.

Authors:  Bingning Xie; Emmanuelle Becker; Igor Stuparevic; Maxime Wery; Ugo Szachnowski; Antonin Morillon; Michael Primig
Journal:  RNA Biol       Date:  2019-03-20       Impact factor: 4.652

Review 4.  DNA repair mechanisms and the bypass of DNA damage in Saccharomyces cerevisiae.

Authors:  Serge Boiteux; Sue Jinks-Robertson
Journal:  Genetics       Date:  2013-04       Impact factor: 4.562

5.  In vivo measurements of interindividual differences in DNA glycosylases and APE1 activities.

Authors:  Isaac A Chaim; Zachary D Nagel; Jennifer J Jordan; Patrizia Mazzucato; Le P Ngo; Leona D Samson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-09       Impact factor: 11.205

6.  An efficient transformation system for Trichoderma atroviride using the pyr4 gene as a selectable marker.

Authors:  Gabriela Calcáneo-Hernández; Erick Rojas-Espinosa; Fidel Landeros-Jaime; José Antonio Cervantes-Chávez; Edgardo Ulises Esquivel-Naranjo
Journal:  Braz J Microbiol       Date:  2020-07-06       Impact factor: 2.476

7.  Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.

Authors:  Mary Ellen Urick; Eun Joo Chung; William P Shield; Naamit Gerber; Ayla White; Anastasia Sowers; Angela Thetford; Kevin Camphausen; James Mitchell; Deborah E Citrin
Journal:  Clin Cancer Res       Date:  2011-06-20       Impact factor: 12.531

8.  Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.

Authors:  Quan Zeng; Zhihai Wang; Chuan Liu; Zhitao Gong; Li Yang; Liang Jiang; Zuxia Ma; Yi Qian; Yucheng Yang; Houyong Kang; Suling Hong; Youquan Bu; Guohua Hu
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

9.  Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.

Authors:  Huiling Xu; Max Yan; Jennifer Patra; Rachael Natrajan; Yuqian Yan; Sigrid Swagemakers; Jonathan M Tomaszewski; Sandra Verschoor; Ewan Ka Millar; Peter van der Spek; Jorge S Reis-Filho; Robert G Ramsay; Sandra A O'Toole; Catriona M McNeil; Robert L Sutherland; Michael J McKay; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2011-01-21       Impact factor: 6.466

10.  Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.

Authors:  Ryutaro Mori; Kazuhiro Yoshida; Toshiyuki Tanahashi; Kazunori Yawata; Junko Kato; Naoki Okumura; Yasuhiro Tsutani; Morihito Okada; Naohide Oue; Wataru Yasui
Journal:  Gastric Cancer       Date:  2012-09-12       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.